雄甾-4-烯-3,6-二酮 | 604-25-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 雄甾-4-烯-3,6-二酮
• 英文名称: androst-4-ene-3,6-dione
• 英文别名: (8S,9S,10R,13S,14S)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,6-dione
• CAS: 604-25-1
• 化学式: C₁₉H₂₆O₂
• 分子量: 286.414
• InChiKey: AGHRVPJHGYJPGR-UNTXSKPGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  雄甾-4-烯-3,6-二酮 在 sodium tetrahydroborate 、 Jones reagent 、 cerium(III) chloride 、 nickel dichloride 作用下， 生成 5α-androstane-3,6-dione
  参考文献：
  名称：

  Synthesis and biological evaluation of steroidal derivatives as selective inhibitors of AKR1B10

  摘要：

  AKR1B10 is a member of human aldo-keto reductase superfamily, and a promising anti-cancer therapeutic target. In this paper, androst-5-ene-3 beta-ol, dehydroepiandrosterone, pregnenolone and cholesterol were used as reactants, sixteen products were obtained through Jones reaction and reduction reaction using NaBH4. Their inhibitory activities against AKR1B10 and AKR1B1 were measured. The most active compound (3a) has the IC50 of 0.50 mu M for AKR1B10, and the most AKR1B10 selective compound (2a) has the IC50 of 0.81 mu M with AKR1B1/AKR1B10 selectivity of 195. In addition, the binding modes of 2a and 3a in the active site of human AKR1B10 were identified by docking. (C) 2014 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2014.04.010
• 作为产物：
  描述：

  雄甾-5-烯-3-醇 在 chromium(VI) oxide 作用下， 生成 雄甾-4-烯-3,6-二酮
  参考文献：
  名称：

  Mel'nikova,V.I. et al., Journal of general chemistry of the USSR, 1971, vol. 41, p. 1643 - 1650

  摘要：

  DOI：

文献信息

• Topical treatment for mastalgia
  申请人：——

  公开号：US20040018991A1

  公开（公告）日：2004-01-29

  A composition for medicinal treatment by means of topical administration is described, which contains an aromatase inhibitor, in addition to conventional constituents of topical forms of administration. The active ingredient or the composition containing this active ingredient is especially suitable for the prophylaxis and for the treatment of mastalgia.

  本文描述了一种用于局部给药的医疗治疗组合物，其中包含一种芳香化酶抑制剂，除了传统的局部给药成分之外。这种活性成分或含有该活性成分的组合物特别适用于乳房疼痛的预防和治疗。
• [EN] 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT<br/>[FR] STEROÏDES SUBSTITUES-17 UTILES POUR LE TRAITEMENT DU CANCER
  申请人：BRITISH TECHNOLOGY GROUP LTD.

  公开号：WO1993020097A1

  公开（公告）日：1993-10-14

  (EN) Compounds of general formula (1) wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R14 represents a hydrogen atom and R15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R14 and R15 together represent a double bond, and R16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or pharmaceutically acceptable acid addition salts, with the proviso that 17-(3-pyridyl)androsta-5,14,16-trien-3$g(b)-ol and 15$g(b)-acetoxy-17-(3-pyridyl)androsta-5,16-dien-3$g(b)-ol and their 3-acetates and 3$g(b)-methoxy-17-(3-pyridyl)androst-16-ene are claimed only for use in therapy are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.(FR) Composés de formule générale (1) dans laquelle X représente le reste des cycles A, B et C d'un stéroïde, R représente un atome d'hydrogène ou un groupe alkyle comprenant de 1 à 4 atomes de carbone, R14 représente un atome d'hydrogène et R15 représente un atome d'hydrogène ou un groupe alkyle ou alcoxy comprenant de 1 à 4 atomes de carbone, ou un groupe hydroxy ou alkylcarbonyloxy comprenant de 2 à 5 atomes de carbone ou R14 et R15 représentent conjointement une liaison double, et R16 représente un atome d'hydrogène ou un groupe alkyle comprenant de 1 à 4 atomes de carbone, sous la forme de bases libres ou de sels d'addition acide pharmaceutiquement acceptables, à condition que 17-(3-pyridyle)androsta-5,14,16-triène-3$g(b)-ol et 15$g(b)-acétoxy-17-(3-pyridyle)androsta-5,16-diène-3$g(b)-ol et leurs 3-acétates et 3$g(b)-méthoxy-17-(3-pyridyle)androst-16-ène sont revendiqués seulement pour usage thérapeutique. Les composés de l'invention sont utiles pour le traitement des affections dépendant de l'androgène, notamment le cancer prostatique, et également des affections dépendant de l'oestrogène telles que le cancer du sein.

  (中文) 通式（1）中X代表类固醇的A，B和C环的残基，R代表氢原子或1至4个碳原子的烷基，R14代表氢原子，R15代表氢原子或1-4个碳原子的烷基或烷氧基，或2至5个碳原子的羟基或烷基羰氧基，或R14和R15共同表示双键，R16代表氢原子或1至4个碳原子的烷基，以自由碱或药学上可接受的酸加成盐的形式存在，但17-(3-吡啶基)雄烯-5,14,16-三烯-3$g(b)-醇和15$g(b)-乙酰氧基-17-(3-吡啶基)雄烯-5,16-二烯-3$g(b)-醇及其3-乙酸酯和3$g(b)-甲氧基-17-(3-吡啶基)雄烯-16-烯仅声称用于治疗，用于治疗雄激素依赖性疾病，特别是前列腺癌，以及雌激素依赖性疾病，如乳腺癌。
• composition and uses for influencing hair growth
  申请人：Schmidt Alfred

  公开号：US20110117218A1

  公开（公告）日：2011-05-19

  The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described.

  该发明描述了一种组合物，该组合物包括至少一种从化学合成芳香化酶抑制剂和大豆和油菜籽提取物中选择的芳香化酶抑制剂和至少一种植物提取物，该植物提取物含有从植物中提取的一个或多个活性成分，所述活性成分从5α还原酶I型和/或II型抑制剂和雄激素受体阻断剂中选择，该组合物例如包含在一种组合物中，并具有影响头发生长的特殊性质。还描述了该组合物的用途。
• Methods and compositions for treating cancer
  申请人：Cougar Biotechnology, Inc.

  公开号：EP2478907A2

  公开（公告）日：2012-07-25

  Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

  本文描述了治疗癌症的方法和组合物。更具体地说，治疗癌症的方法包括施用 17α- 羟化酶/C17,20-赖氨酸酶抑制剂，如醋酸阿比特龙（即 3β-乙酰氧基-17-(3-吡啶基) 雄甾-5,16-二烯），与至少一种额外的治疗剂如抗癌剂或类固醇结合使用。此外，还公开了包含 17α- 羟化酶/C17,20-裂解酶抑制剂和至少一种额外治疗剂（如抗癌剂或类固醇）的组合物。
• COMPOSITIONS FOR TREATING CANCER
  申请人：Janssen Oncology, Inc.

  公开号：EP3804730A1

  公开（公告）日：2021-04-14

  Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

  本文描述了治疗癌症的方法和组合物。更具体地说，治疗癌症的方法包括施用 17α- 羟化酶/C17,20-赖氨酸酶抑制剂，如醋酸阿比特龙（即 3β-乙酰氧基-17-(3-吡啶基) 雄甾-5,16-二烯），与至少一种额外的治疗剂如抗癌剂或类固醇结合使用。此外，还公开了包含 17α- 羟化酶/C17,20-裂解酶抑制剂和至少一种额外治疗剂（如抗癌剂或类固醇）的组合物。